Cargando…
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
BACKGROUND: Although guidelines do not recommend computerised tomography (CT), positron emission tomography (PET) or magnetic resonance imaging (MRI) for the staging or follow-up of asymptomatic patients with non-metastatic breast cancer, they are often requested in routine clinical practice. The ai...
Autores principales: | De Placido, S, De Angelis, C, Giuliano, M, Pizzi, C, Ruocco, R, Perrone, V, Bruzzese, D, Tommasielli, G, De Laurentiis, M, Cammarota, S, Arpino, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355929/ https://www.ncbi.nlm.nih.gov/pubmed/28170371 http://dx.doi.org/10.1038/bjc.2017.24 |
Ejemplares similares
-
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015) -
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015) -
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021) -
Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021) -
Tumor characteristics and prognosis in familial breast cancer
por: Arpino, G., et al.
Publicado: (2016)